What Happened to Pfizer Inc.?
Pfizer Inc. (PFE) experienced a significant surge during the COVID-19 pandemic due to its vaccine and antiviral treatments, reaching record revenues in 2022. However, with declining demand for COVID-19 products, the company has faced revenue contraction and initiated a major cost-cutting program, while strategically acquiring Seagen for $43 billion to bolster its oncology pipeline and diversify its growth drivers. As of early 2026, Pfizer is focused on integrating new acquisitions, advancing a robust pipeline in oncology and other therapeutic areas, and managing costs to return to sustainable growth by the end of the decade.
Quick Answer
Pfizer Inc. (PFE stock) has transitioned from a period of unprecedented growth driven by COVID-19 vaccines and treatments to a strategic 'reset' phase. Following record revenues in 2022, the company saw significant declines in COVID-19 product sales in 2023 and 2025, leading to a focus on cost-cutting and portfolio diversification. A key move was the $43 billion acquisition of Seagen, completed in December 2023, to strengthen its oncology presence. As of March 2026, Pfizer is reaffirming its 2026 financial guidance, anticipating continued operational growth in its non-COVID portfolio, driven by new product launches and its enhanced oncology pipeline, while managing the impact of patent expirations and ongoing cost realignment efforts.
📊Key Facts
📅Complete Timeline14 events
First COVID-19 Vaccine Approval
Pfizer and BioNTech's COVID-19 vaccine, Comirnaty, receives Emergency Use Authorization (EUA) from the FDA, marking a pivotal moment in the pandemic response and for Pfizer's revenue.
Paxlovid Receives EUA
Pfizer's oral antiviral treatment for COVID-19, Paxlovid, receives Emergency Use Authorization from the FDA, further boosting the company's pandemic-related revenue streams.
Record Annual Revenue
Pfizer reports an all-time high annual revenue of over $100 billion, largely driven by sales of Comirnaty and Paxlovid.
Announces Seagen Acquisition
Pfizer announces its intent to acquire Seagen Inc., a biotechnology company specializing in cancer medicines, for approximately $43 billion, signaling a major strategic shift towards oncology.
Launches Cost Realignment Program
Amidst declining COVID-19 product sales, Pfizer initiates an enterprise-wide cost-cutting program targeting $3.5 billion in savings through 2024.
Completes Seagen Acquisition
Pfizer successfully closes the acquisition of Seagen for $43 billion, officially integrating its oncology pipeline and operations.
Increases Cost Savings Target
Pfizer raises its cost-cutting target to $4 billion by the end of 2024, an additional $500 million from its initial plan, reflecting ongoing efforts to streamline operations.
Announces Further Cost-Cutting Initiatives
Pfizer unveils another multi-year cost reduction program, aiming for approximately $1.5 billion in savings by 2027, primarily from cost of goods sold.
Total Savings Target Reaches $7.7 Billion
Pfizer increases its overall cost-savings drive target to $7.7 billion through 2027, with $4.5 billion in net savings expected by the end of 2025.
Provides 2026 Financial Guidance
Pfizer forecasts 2026 revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, reflecting continued declines in COVID-19 product sales and patent expirations.
Reports Q4 and Full-Year 2025 Results
Pfizer announces Q4 2025 revenues of $17.6 billion and full-year 2025 revenues of $62.6 billion, reaffirming its 2026 guidance and highlighting 6% operational growth in its non-COVID portfolio for the full year.
Highlights Obesity and Oncology as Key Catalysts
Trefis identifies Pfizer's re-entry into the obesity franchise with differentiated GLP-1 candidates and accelerated oncology growth from new modalities as key catalysts for potential stock surges in mid-to-late 2026.
Q1 2026 Dividend Payment
Pfizer pays its first-quarter 2026 cash dividend of $0.43 per share, marking its 349th consecutive quarterly dividend.
Talzenna Shows Positive Phase 3 Results
Pfizer announces that its anti-cancer drug Talzenna, in combination with Xtandi, met the primary endpoint in the TALAPRO-3 trial for prostate cancer, indicating strong performance in its oncology portfolio.
🔍Deep Dive Analysis
Pfizer Inc. (PFE) witnessed an extraordinary period of growth during the COVID-19 pandemic, primarily driven by its highly successful Comirnaty vaccine, developed with BioNTech, and its antiviral treatment, Paxlovid. This led to record revenues, peaking at over $100 billion in 2022. However, as the global health crisis subsided and demand for these products waned, Pfizer faced a significant revenue decline, with 2023 seeing a 41.1% decrease from 2022.
In response to this 'post-COVID reset' and to mitigate the impact of upcoming patent expirations, Pfizer embarked on a multi-faceted strategy. A critical turning point was the announcement in March 2023, and subsequent completion in December 2023, of the acquisition of Seagen Inc. for approximately $43 billion. This strategic move was aimed at significantly bolstering Pfizer's oncology portfolio, with Seagen's antibody-drug conjugates (ADCs) expected to contribute over $10 billion in risk-adjusted revenues by 2030 and potentially double Pfizer's early-stage oncology clinical pipeline.
Alongside portfolio expansion, Pfizer initiated an aggressive enterprise-wide 'Cost Realignment Program' in October 2023, initially targeting $3.5 billion in savings by the end of 2024. This target was subsequently increased multiple times, reaching $4 billion by December 2023 and further expanding to $7.7 billion in total savings through 2027 by April 2025, with the majority expected by the end of 2026. These cost-cutting measures, which included layoffs, were designed to improve operating margins and financial discipline.
Looking at recent performance, Pfizer reported full-year 2025 revenues of $62.6 billion, a 2% operational decline from 2024, primarily due to lower COVID-19 product contributions. However, excluding COVID-19 products, the company achieved 6% operational revenue growth in 2025. For the fourth quarter of 2025 (reported February 2026), revenues were $17.6 billion, a 3% operational decrease, but non-COVID product performance showed solid 9% operational growth. Pfizer also reaffirmed its full-year 2026 revenue guidance in the range of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, acknowledging a further $1.5 billion decline in COVID-19 product sales and a similar impact from loss of exclusivity (LOE) on other products.
As of March 2026, Pfizer's pipeline remains a key focus, with significant data readouts and pivotal study starts anticipated throughout the year, particularly in oncology and its re-entry into the obesity market with differentiated GLP-1 candidates. The company continues to pay a consistent quarterly dividend, with the first-quarter 2026 dividend of $0.43 per share paid on March 6, 2026. While PFE stock has shown volatility, analysts generally hold a 'Hold' consensus, with price targets suggesting modest upside, as investors weigh short-term revenue headwinds against the long-term potential of its diversified pipeline and cost efficiencies.
What If...?
Explore alternate histories. What if Pfizer Inc. made different choices?